Abstract
The Rip1Tag2 transgenic mouse model of β-cell carcinogenesis has been instrumental in studying various aspects of tumor angiogenesis and in investigating the response to anti-angiogenic therapeutics. Thereby, the in-depth assessment of blood and lymphatic vessel phenotypes and functionality represents key experimental analyses. In this chapter, we describe basic protocols to assess tumor blood vessel morphology (pericyte coverage), functionality (perfusion, leakiness, and hypoxia), lymphatic tumor coverage, and tumor cell proliferation and apoptosis based on immunofluorescence microscopy analysis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115–122
Christofori G, Naik P, Hanahan D (1994) A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369:414–418
Bill R, Fagiani E, Zumsteg A et al (2015) Nintedanib is a highly effective therapeutic for neuroendocrine carcinoma of the pancreas (PNET) in the Rip1Tag2 transgenic mouse model. Clin Cancer Res 21:4856–4867
Folkman J, Watson K, Ingber D et al (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58–61
Inoue M, Hager JH, Ferrara N et al (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193–202
Albrecht I, Kopfstein L, Strittmatter K et al (2010) Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 5:e14109
Bergers G, Brekken R, McMahon G et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744
Fagiani E, Lorentz P, Kopfstein L et al (2011) Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res 71:5717–5727
Gannon G, Mandriota SJ, Cui L et al (2002) Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res 62:603–608
Mandriota SJ, Jussila L, Jeltsch M et al (2001) Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672–682
Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231
Schomber T, Kopfstein L, Djonov V et al (2007) Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 67:10840–10848
Tuveson D, Hanahan D (2011) Translational medicine: cancer lessons from mice to humans. Nature 471:316–317
Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417–427
Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989
Mazzone M, Dettori D, Leite de Oliveira R et al (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839–851
Armulik A, Genove G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21:193–215
Kopfstein L, Veikkola T, Djonov VG et al (2007) Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol 170:1348–1361
Hager JH, Hodgson JG, Fridlyand J et al (2004) Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. Cancer Res 64:2406–2410
Kuzmanov A, Hopfer U, Marti P et al (2014) LIM-homeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine PDGF-B signaling. Mol Oncol 8:401–416
Maione F, Capano S, Regano D et al (2012) Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest 122:1832–1848
Anderberg C, Cunha SI, Zhai Z et al (2013) Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 210:563–579
Rigamonti N, Kadioglu E, Keklikoglou I et al (2014) Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 8:696–706
Sennino B, Ishiguro-Oonuma T, Schriver BJ et al (2013) Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res 73:3692–3703
Sennino B, Ishiguro-Oonuma T, Wei Y et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270–287
Singh M, Couto SS, Forrest WF et al (2012) Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol 227:417–430
Hypoxyprobe, Inc. http://www.hypoxyprobe.com/faq.html. Accessed 27 Aug 2015
Hunter KE, Quick ML, Sadanandam A et al (2013) Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 8:e64472
Acknowledgement
This work was supported by a Swiss National Science Foundation MD-PhD student fellowship to R.B.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Bill, R., Christofori, G. (2016). The Rip1Tag2 Transgenic Mouse Model. In: Ribatti, D. (eds) Tumor Angiogenesis Assays. Methods in Molecular Biology, vol 1464. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3999-2_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3999-2_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3997-8
Online ISBN: 978-1-4939-3999-2
eBook Packages: Springer Protocols